TICKERNERD
Menu
ACRVACRVHealthcare · Biotechnology

ACRV Stock Forecast: Acrivon Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.21
+0.45% on the day

The 7 Wall Street analysts covering Acrivon Therapeutics, Inc. hold a median 12-month price target of $11 — +375.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 21 Aug 2026 — in the upper half.

Market cap
$94.7M
Ticker Nerd rank
68 / 100
Median analyst target
$11
Analysts covering
7
Total return, dividends reinvested
1W
+13.3%
1M
+26.3%
YTD
−8.3%
1Y
+67.4%
From 52W high
−26.6%
From 52W low
+71.3%
$1.29
$3.01
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACRV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Acrivon Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
68 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
79
Revisions
77
Size
76
Growth
68
Momentum
55
Issuance
45
Quality
44
Volatility
38
Value
26

Accruals (79): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (26): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACRV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACRV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26ACRVHigh $19Median $11Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $7Median $11High $19

The green dot is the last close — the median target sits +375.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Jan 2026Piper SandlerMaintainsOverweight$6.00 → $8.00
25 Nov 2025HC Wainwright & Co.ReiteratesBuy—
14 Aug 2025OppenheimerMaintainsOutperform—
16 May 2025Jones TradingDowngradeHold—
15 May 2025OppenheimerMaintainsOutperform—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
28 Mar 2025OppenheimerMaintainsOutperform—
26 Mar 2025Cantor FitzgeraldReiteratesOverweight—
26 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—
26 Mar 2025HC Wainwright & Co.MaintainsBuy—
31 Jan 2025Cantor FitzgeraldInitiatesOverweight—
14 Nov 2024BMO CapitalMaintainsOutperform—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright& Co.ReiteratesBuy—
16 Sept 2024BMO CapitalReiteratesOutperform—
16 Sept 2024HC Wainwright & Co.ReiteratesBuy—
16 Sept 2024JMP SecuritiesReiteratesMarket Outperform—
16 Sept 2024Ladenburg ThalmannUpgradeBuy—
13 Aug 2024HC Wainwright & Co.ReiteratesBuy—
15 May 2024BMO CapitalReiteratesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACRV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ACRV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
2
Fundamentals

Acrivon Therapeutics, Inc. (ACRV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.1×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
1.1×

Cheaper than 75% of US stocks

EV / EBITDA
−0.1×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−64.6%

Higher than 18% of US stocks

Return on assets
−38.0%

Higher than 11% of US stocks

Dividend yield
74.2%

Higher than 98% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ACRV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACRVAcrivon Therapeutics, Inc.$94.7M
68
CGTXCognition Therapeutics, Inc.$94.7M
39
FBIOFortress Biotech, Inc.$95.3M
78
BMEABiomea Fusion, Inc.$96.9M
50
YARWYarrow Bioscience, Inc.$97.2M
51
PYPDPolyPid Ltd.$97.3M
50
ATRAAtara Biotherapeutics, Inc.$97.4M
66

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Acrivon Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACRV news & analysis

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

GlobeNewsWire · 12 Aug 2026neutral

Acrivon Therapeutics reported its second quarter 2026 financial results and highlighted upcoming clinical data catalysts. The company confirmed that the ACR-368 Phase 2b prespecified interim analysis and data from the all-comer serous endometrial cancer treatment arms remain on track for the second half of 2026.

Why it matters — ACRV watchers would track this update because it confirms the timeline outlook for key ACR-368 clinical data readouts in serous endometrial cancer, which are anticipated catalysts for the company in the latter half of 2026.

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

GlobeNewsWire · 5 Aug 2026positive

Acrivon Therapeutics announced that ACR-2316, a potential first-in-class WEE1/PKMYT1 inhibitor, has advanced into the randomized dose expansion portion of its ongoing Phase 1/2 study. The program will evaluate the drug at selected 120 mg and 160 mg once-daily oral weekly doses across AP3-informed solid tumor populations, including biomarker-selected small cell lung cancer, squamous non-small cell lung cancer, lung adenocarcinoma, and endometrial, cervical, and esophago-gastric junction cancers.

Why it matters — The advancement of ACR-2316 into randomized dose expansion marks a key clinical milestone for Acrivon's lead pipeline candidate and demonstrates application of its AP3 platform in patient selection.

FAQ

Frequently asked questions about ACRV stock

What is the ACRV stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Acrivon Therapeutics, Inc. have a median 12-month price target of $11, with estimates ranging from $7 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACRV stock a buy right now?

Of the 7 analysts covering Acrivon Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Acrivon Therapeutics, Inc. 68 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACRV?

As at 21 Aug 2026, Acrivon Therapeutics, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (79 of 100).

Will ACRV stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +375.1% from the last close, and Ticker Nerd's factor model ranks Acrivon Therapeutics, Inc. 68 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACRV stock forecast for 2030?

No analyst covering Acrivon Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACRV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $19 over the next 12 months.

How has ACRV stock performed over the past year?

Acrivon Therapeutics, Inc. returned +67.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Acrivon Therapeutics, Inc. do?

Acrivon Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology medicines tailored for patients whose tumors are predicted to be sensitive to specific treatments through its proprietary generative phosphoproteomics platform.

What is the latest news on ACRV?

The most recent item we track (GlobeNewsWire, 12 Aug 2026): "Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts". Acrivon Therapeutics reported its second quarter 2026 financial results and highlighted upcoming clinical data catalysts. The company confirmed that the ACR-368 Phase 2b prespecified interim analysis and data from the all-comer serous endometrial cancer treatment arms remain on track for the second half of 2026.

Company

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology medicines tailored for patients whose tumors are predicted to be sensitive to specific treatments through its proprietary generative phosphoproteomics platform. The company operates the Acrivon Predictive Precision Proteomics (AP3) platform, which generates drug-specific proprietary OncoSignature companion diagnostics to precisely identify suitable patients for its drug candidates, enabling a precision medicine approach in cancer therapy. Its lead clinical candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, advancing in a registrational-intent Phase 2 study for endometrial cancer and showing activity in platinum-resistant ovarian cancer and squamous cell carcinomas such as head and neck and anal cancers. Additionally, ACR-2316, a novel WEE1/PKMYT1 inhibitor designed using AP3 for enhanced single-agent potency, is in Phase 1 clinical trials. Headquartered in Watertown, Massachusetts, Acrivon Therapeutics Inc. plays a key role in advancing targeted oncology therapies by integrating proteomics-driven patient selection with innovative drug discovery to address unmet needs in precision cancer care.

CEO Dr. Peter Blume-Jensen M.D., Ph.D. · 74 employees · United States · https://acrivon.com